Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke.

Chi Phuong NguyenMaarten Mh LahrDurk-Jouke van der ZeeHenk van VoorstYvo B W E M RoosMaarten UyttenboogaartErik Buskens

Published in: European stroke journal (2023)

Tenecteplase treatment was cost-effective for all AIS patients (including AIS patients with LVO) compared to alteplase. The finding supports the broader use of tenecteplase in acute stroke care, as health outcomes improve at acceptable costs while having practical advantages, and a similar safety profile.

Keyphrases

acute ischemic stroke
end stage renal disease
healthcare
newly diagnosed
ejection fraction
chronic kidney disease
palliative care
peritoneal dialysis
prognostic factors
health insurance